BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32678966)

  • 1. The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation.
    Hedayatyanfard K; Haddadi NS; Ziai SA; Karim H; Niazi F; Steckelings UM; Habibi B; Modarressi A; Dehpour AR
    Exp Dermatol; 2020 Sep; 29(9):902-909. PubMed ID: 32678966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review.
    Iannello S; Milazzo P; Bordonaro F; Belfiore F
    MedGenMed; 2006 Dec; 8(4):60. PubMed ID: 17415337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of angiotensin receptor blockers in skin pathologies.
    Hedayatyanfard K; Khalili A; Karim H; Nooraei S; Khosravi E; Haddadi NS; Dehpour AR; Bayat G
    Iran J Basic Med Sci; 2023; 26(7):732-737. PubMed ID: 37396936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin system and experimental heart failure.
    Wollert KC; Drexler H
    Cardiovasc Res; 1999 Sep; 43(4):838-49. PubMed ID: 10615411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Angiotensin II and AT
    Niazi F; Hooshyar SH; Hedayatyanfard K; Ziai SA; Doroodgar F; Niazi S; Habibi B; Asadirad A
    J Clin Aesthet Dermatol; 2018 Oct; 11(10):36-39. PubMed ID: 30519378
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.
    Lee HJ; Jang YJ
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of keloid and hypertrophic scar formation.
    Tuan TL; Nichter LS
    Mol Med Today; 1998 Jan; 4(1):19-24. PubMed ID: 9494966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of chymase in the local renin-angiotensin system in keloids: inhibition of chymase may be an effective therapeutic approach to treat keloids.
    Wang R; Chen J; Zhang Z; Cen Y
    Drug Des Devel Ther; 2015; 9():4979-88. PubMed ID: 26357464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan ointment relieves hypertrophic scars and keloid: A pilot study.
    Hedayatyanfard K; Ziai SA; Niazi F; Habibi I; Habibi B; Moravvej H
    Wound Repair Regen; 2018 Jul; 26(4):340-343. PubMed ID: 30099811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling.
    Fang F; Huang RL; Zheng Y; Liu M; Huo R
    J Dermatol Sci; 2016 Aug; 83(2):95-105. PubMed ID: 27211019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the renin-angiotensin system in skin physiology and pathophysiology.
    Silva IMS; Assersen KB; Willadsen NN; Jepsen J; Artuc M; Steckelings UM
    Exp Dermatol; 2020 Sep; 29(9):891-901. PubMed ID: 32697884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids.
    Ulrich D; Ulrich F; Unglaub F; Piatkowski A; Pallua N
    J Plast Reconstr Aesthet Surg; 2010 Jun; 63(6):1015-21. PubMed ID: 19464975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
    Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
    Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation.
    Colwell AS; Phan TT; Kong W; Longaker MT; Lorenz PH
    Plast Reconstr Surg; 2005 Oct; 116(5):1387-90; discussion 1391-2. PubMed ID: 16217483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperplastic scars and keloids. Part I: basics and prevention].
    Baisch A; Riedel F
    HNO; 2006 Nov; 54(11):893-904; quiz 905. PubMed ID: 17041777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II regulates phosphoinositide 3 kinase/Akt cascade via a negative crosstalk between AT1 and AT2 receptors in skin fibroblasts of human hypertrophic scars.
    Liu HW; Cheng B; Yu WL; Sun RX; Zeng D; Wang J; Liao YX; Fu XB
    Life Sci; 2006 Jun; 79(5):475-83. PubMed ID: 16522324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The link between hypertension and pathological scarring: does hypertension cause or promote keloid and hypertrophic scar pathogenesis?
    Huang C; Ogawa R
    Wound Repair Regen; 2014; 22(4):462-6. PubMed ID: 24899409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar.
    Sideek MA; Teia A; Kopecki Z; Cowin AJ; Gibson MA
    J Mol Histol; 2016 Feb; 47(1):35-45. PubMed ID: 26644005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.